Indicated for the treatment of adult patients with metastatic NSCLC: 🔹 First-line treatment: Patients whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. 🔹 Second-line treatment: Patients with EGFR T790M mutation-positive NSCLC (detected after progression on prior EGFR TKI therapy). 🔹 Adjuvant therapy: After tumor resection in patients with EGFR mutation-positive NSCLC.

Dosage and administration

Packaging: 80 mg tablets. ⚠️ ADMINISTRATION PROTOCOL: Recommended Dose: 80 mg orally once daily. Timing: Take at the same time each day, with or without food. Administration: Swallow the tablet whole with water. Do not crush, split, or chew. For Difficulty Swallowing: The tablet can be dispersed in 50 mL of non-carbonated water (stir until dispersed, do not crush) and swallowed immediately.

Hypersensitivity to Osimertinib. Pregnancy and breastfeeding (embryo-fetal toxicity). History of Interstitial Lung Disease (ILD) or drug-induced pneumonitis. Concomitant use with St. John's Wort.

Common adverse reactions include: 🩸 Cardiac/Labs: QT interval prolongation, decreased leukocytes/platelets. 📉 Dermatologic: Rash, dry skin, paronychia (nail infection/inflammation), pruritus. 🌀 Respiratory/GI: Diarrhea, stomatitis, interstitial lung disease (ILD) — requires immediate medical attention. Patients should monitor for nail changes and skin rash regularly.

Osicent — Osimertinib 80 mg, 30 pcs, Incepta Pharmaceuticals

100% original product

Active ingredient

Osimertinib

Manufacturer

Incepta Pharmaceuticals

Dosage 80 mg

Dosage form Tablets

Tablets per pack 30

Osicent (Osimertinib) 80 mg Tablets

Name: Osicent
Brand: Incepta Pharmaceuticals
SKU: PROD-142
Price: 12306 UAH
Availability: InStock

12306₴ ~~13185₴~~ -7%

Osicent 80 mg (Osimertinib) is a third-generation EGFR tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC).

Manufacturer: Incepta Pharmaceuticals. Each pack contains 30 tablets. It is designed to inhibit both EGFR-sensitizing and EGFR T790M-resistance mutations, effectively blocking tumor growth.

Key Feature:

Osimertinib crosses the blood-brain barrier, showing significant efficacy against central nervous system (CNS) metastases.

Indicated for the treatment of adult patients with metastatic NSCLC:

🔹 First-line treatment: Patients whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
🔹 Second-line treatment: Patients with EGFR T790M mutation-positive NSCLC (detected after progression on prior EGFR TKI therapy).
🔹 Adjuvant therapy: After tumor resection in patients with EGFR mutation-positive NSCLC.

Packaging: 80 mg tablets.

⚠️ ADMINISTRATION PROTOCOL:

Recommended Dose: 80 mg orally once daily.
Timing: Take at the same time each day, with or without food.
Administration: Swallow the tablet whole with water. Do not crush, split, or chew.
For Difficulty Swallowing: The tablet can be dispersed in 50 mL of non-carbonated water (stir until dispersed, do not crush) and swallowed immediately.

Hypersensitivity to Osimertinib.
Pregnancy and breastfeeding (embryo-fetal toxicity).
History of Interstitial Lung Disease (ILD) or drug-induced pneumonitis.
Concomitant use with St. John's Wort.

Common adverse reactions include:

🩸 Cardiac/Labs: QT interval prolongation, decreased leukocytes/platelets.
📉 Dermatologic: Rash, dry skin, paronychia (nail infection/inflammation), pruritus.
🌀 Respiratory/GI: Diarrhea, stomatitis, interstitial lung disease (ILD) — requires immediate medical attention.
Patients should monitor for nail changes and skin rash regularly.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.03.2026